Eli Lilly's weight-loss drug Zepbound could treat sleep apnea

Eli Lilly said Wednesday that its weight-loss drug Zepbound improved symptoms in two late-stage trials of patients with obstructive sleep apnea.If treating sleep apnea ultimately earns an FDA green light, it could expand insurance coverage for the drug and reshape treatment for a dangerous sleep condition affecting more than

Lilly shares jumped more than 2.5% on the announcement, before settling to close up 0.5%. Shares of ResMed, a maker of CPAP machines used in existing positive airway pressure therapy, closed down 6%.Obstructive sleep apnea is closely associated with obesity, as fat deposits in a person's tongue and upper airway can restrict airflow to the lungs during sleep.

Loud snoring is the most obvious symptom, but people suffering from OSA will repeatedly stop and start breathing during sleep. Those diagnosed with severe cases can experience more thanthe drug Lilly brands as Zepbound — suffered 27 fewer breathing events per hour than the baseline.Adding OSA to the list of things Zepbound can treat would likely increase insurance coverage for the drug.

States and corporate health plans have been tightening access to drugs like Ozempic and Zepbound, the popular class of weight-loss and diabetes drugs known as GLP-1s, as a surge in usage has led to soaring costs for plan providers, Lilly said it plans to submit data to the FDA and global regulators beginning mid-year in hopes of gaining approval for OSA treatment.Share on linkedin

Weight Loss

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Most doses of Eli Lilly's Zepbound, Mounjaro in short supply through June, FDA saysThe insatiable demand for weight loss and diabetes drugs is still trouncing supply, even as Eli Lilly and Novo Nordisk work to increase production capacity.
Source: CNBC - 🏆 12. / 72 Read more »

Eli Lilly’s weight loss drug Zepbound found to reduce sleep apnea, company saysBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Source: NBCNewsHealth - 🏆 707. / 51 Read more »

Eli Lilly's Zepbound shows promise as a sleep apnea treatment in late-stage trialsThe pharmaceutical giant plans to present the trial data at an upcoming medical conference and submit them to the U.S. Food and Drug Administration mid-year. 
Source: NBCPhiladelphia - 🏆 569. / 51 Read more »

Eli Lilly's weight loss drug reduces sleep apnea, study showsEli Lilly noted that tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults that have both obstructive sleep apnea and obesity.
Source: FoxBusiness - 🏆 458. / 53 Read more »

Eli Lilly weight loss injection drug also helps with obstructive sleep apnea, company saysThe Eli Lilly weight loss injection Zepbound reduced the intensity of obstructive sleep apnea in patients by nearly two-thirds, the pharmaceutical giant announced Wednesday.
Source: WashTimes - 🏆 235. / 63 Read more »

Stocks making the biggest premarket moves: Eli Lilly, Travelers, United Airlines, Alcoa and moreThese are the stocks posting the largest moves in the premarket.
Source: CNBC - 🏆 12. / 72 Read more »